Kornimate/medical-research-clean huggingface dataset:
phase iii study of compound danshen dripping pills to treat diabetic retinopathy

Conditions: Non-proliferative Diabetic Retinopathy

Summary: the purpose of this study is to evaluate the efficacy and safety of compound danshen dripping pills in patients with diabetic retinopathy(syndrome of qi-stagnation and blood stasis).

compound danshen dripping pills is a kind of traditional chinese medicine(tcm), consists of danshen (radix salviae miltiorrhizae), sanqi (radix notoginseng) and borneol. this study is being conducted to evaluate the efficacy and safety of compound danshen dripping pills in patients with diabetic retinopathy(syndrome of qi-stagnation and blood stasis), when compared with placebo.

Eligibility criteria:
inclusion criteria: 1. diagnosed with non-proliferative diabetic retinopathy(npdr) and tcm syndrome differentiation of qi-stagnation and blood stasis. 2. aged 30-70 years 3. voluntary signs the informed consent one eye met the inclusion criteria can be used as research object, if both eyes met the inclusion criteria, please record respectively, and select one eye for efficacy evaluation with reference to the following principles: when the two eyes of fundus conditions in different clinical stage, choose the more serious one. when the two eyes of fundus conditions in the same clinical stage, choose the eye easier for clinical operation. exclusion criteria: 1. hbalc\>8%, sustained hyperglycemia. 2. the patients who have been received the therapy of retina laser photocoagulation or diagnosed with proliferative diabetic retinopathy (one or two eyes). 3. diabetic retinopathy caused by type 1 diabetes mellitus. 4. combined with glaucoma, uveitis, ocular neuropathy and severe cataract etc. 5. combined with primarily severe diseases such as cardiovascular, hepatic，renal illness , hemopoietic system disease, and psychosis. serum transaminase is higher than the limit of normal value of 1.5 times. 6. diabetic nephropathy with renal failure (azotemia or uremia). 7. for women of child-bearing potential: pregnant or lactating or intending to become pregnant. having any allergic reaction to some drugs. 8. participated in other clinical trial within 3 months. 9. used drugs for the treatment of diabetic retinopathy within 1 week. 10. blood pressure \> 160/100 (systolic above 160 or diastolic above 100).
cryoablation for benign gastrointestinal anastomotic strictures

Conditions: Esophageal Stricture; Duodenal Stricture; Jejunal Stricture; Anastomotic Stricture of Small Intestine

Summary: anastomotic stricture is a common complication following foregut surgery. the standard of care for these benign foregut anastomotic strictures is balloon dilatation. however, re-stenosis of strictures is also common, requiring frequent repetition of balloon dilatation. cryotherapy is a novel therapy that may improve clinical outcomes following dilatation. the purpose of the present study is to conduct a randomized controlled trial to characterize the impact of cryotherapy on clinical outcomes and complications for benign anastomotic strictures following esophagectomy, gastrectomy, and bariatric surgery.


Eligibility criteria:
inclusion critieria * history of esophagectomywith primary anastomosis * history of gastrectomy with primary anastomosis * history of bariatric surgery with primary anastomosis * history of anastomotic stricture * history of balloon dilatation at keck hospital of the university of southern california exclusion critieria * patients treated at medical centers other than keck hospital of the university of southern california * history of anastomotic stent placement
the prognostic value of 18f-pfpn pet imaging in patients with malignant melanoma

Conditions: Melanoma

Summary: this is a monocentric prospective study. this study aims to investigate the prognostic value of the novel melanin-targeted imaging modality 18f-pfpn pet in patients with melanoma and seek independent prognostic factors for progression-free survival (pfs) and overall survival (os). the patients with clinically highly suspected or confirmed melanoma who underwent 18f-pfpn and 18f-fdg pet scans will be enrolled consecutively. patients' pet images, clinical characteristics, and follow-up information will be collected for prognostic analyses. this study plans to set the sample size as 100 cases.

melanoma is an aggressive malignancy with a high mortality rate. accurate diagnosis and prognostic risk assessment are essential to the clinical management of melanoma. melanin is present in most melanoma and has become a potential target for melanoma. this team has successfully synthesized a positron nuclide targeting melanin probe named 18f-pfpn (18f-n-(2-diethylaminoethyl)-4-(2-\[2-ethoxy\]-ethoxy) pyridine), which has been proven to be safe and well-tolerated. it has shown excellent diagnostic value in both primary and metastatic melanoma. this prospective study was designed to further investigate the prognostic value of 18f-pfpn for melanoma and compare it with the general metabolic imaging agent 18f-fdg. in this study, patients with clinically highly suspected or confirmed melanoma who underwent 18f-pfpn and 18f-fdg pet scans will be enrolled consecutively. patients' pet images, clinical characteristics, and follow-up information will be collected for prognostic analyses.

Eligibility criteria:
inclusion criteria: * patients with histopathologically confirmed melanoma; * patients with complete clinical and follow-up data (including tnm stage, subtypes, and treatment strategies). exclusion criteria: * uncertain histopathology; * a history of other malignancies.
study for turoctocog alfa treatment regimen in iraqi haemophilia a patients

Conditions: Congenital Bleeding Disorder; Haemophilia A

Summary: the study has descriptive purposes, with aim of assessing how turoctocog alfa is used in the everyday practice and to provide a baseline for the management of haemophilia a and does not involve any change in the clinical management of participants. data will be extrapolated from the existing paper based medical records and uploaded to an electronic database specifically created for the study. baseline information/history will be recorded at time of switching from previous fviii replacement therapy to turoctocog alfa from the enrolled participants and outcomes will be collected according to participants visit format.


Eligibility criteria:
inclusion criteria: * paediatric and adult male patients * on-demand and prophylactic patients with haemophilia a (any severity) * only previously treated patients (previous fviii replacement therapy) will be included in the study exclusion criteria: * patients diagnosed with coagulation disorders other than haemophilia a such as von willebrand disease * patients with documented presence of any fviii inhibitor
synchronous and asynchronous telerehabilitation methods in patients with cervical disc herniation

Conditions: Cervical Disc Herniation

Summary: this was a randomized controlled trial conducted to examine the changes in the pain, physical function, quality of life, and kinesiophobia of participants with non-specific neck pain in marmara university physiotherapy and rehabilitation department. this study was approved by the clinical studies ethics committee of marmara university faculty of health sciences in january 2022 and was carried out in accordance with the declaration of helsinki. the participants were informed about the study and their consent was obtained.


Eligibility criteria:
inclusion criteria: * participants between the ages of 18-65, * who had access to the internet and smartphone, * had the ability to conduct video calls were included in the study. exclusion criteria: * participants were excluded if they had covid-19, * had surgery in the last 6 months, * received physiotherapy treatment. * had a condition that prevented them from exercising.
a comparison between bladder dissection before and after uterine incision during cesarean section for placenta accreta spectrum: a randomized controlled study

Conditions: Placenta Accreta

Summary: the worldwide incidence of placenta accreta spectrum is increasing, following the trend of rising caesarean delivery. it is an heterogeneous condition associated with a high maternal morbidity and mortality rate (jauniaux et al., 2018). caesarean hysterectomy is considered the gold standard for the treatment of placenta accreta. also this radical approach is associated with high rates of severe maternal morbidity as hemorrhage and insult to surrounding organs during surgery (hoffman et al., 2010). surgeons should be able to dissect the bladder safely and confidently through minimally invasive techniques, to avoid surgical injury, it is important to use anatomic landmarks, minimize the use of cauterization (farhat and casale, 2018). all centers are encouraged to develop guidelines to manage the potential urologic complications of these cases tailored to their resources (taneja and shah, 2017). this study aims to evaluate the timing of bladder dissection in caesarean section in patient with placenta accreta spectrum.

objective: try to provide preliminary data to judge between two different approaches during caesarean section for morbidly adherent placenta, that's are bladder dissection before and after uterine incision as regard operative time, blood loss, and incidence of urological injuries. research question: - does bladder dissection after uterine incision in caesarean sections with pas avoids bladder injuries compared to bladder dissection before uterine incision and does it affects operative time and blood loss. research hypothesis: * null hypothesis (h₀): there is no significant difference in performing bladder dissection prior nor after uterine incision in caesarean sections with pas * alternative hypothesis (h₁):. bladder dissection before uterine incision in caesarean sections with pas has superior outcomes compared to bladder dissection after uterine incision.

Eligibility criteria:
inclusion criteria: * women with bmi at or under 35kg/m2 * women with history of at least previous two caesarean section * gestational age more than 32 weeks with viable fetus. * women with any degree of placenta previa. * women with placenta falling in the pas. * willing and able to provide informed consent. exclusion criteria: * o history of urinary bladder injury. * history of urinary or renal disorders * women with coagulation disorders or on anticoagulation therapy. * patients who are hemodynamically unstable before skin incision
an extension study to evaluate the safety and efficacy of celgosivir and peginterferon alfa-2b, with or without ribavirin, in patients with chronic hepatitis c genotype 1 infection

Conditions: Hepatitis C, Chronic

Summary: this is an extension study of hcv-05-002. the objective of this study is to evaluate the safety and efficacy of celgosivir plus peginterferon alfa-2b, with or without ribavirin, for an additional 36 weeks in patients with chronic hepatitis c genotype 1 infection.


Eligibility criteria:
inclusion criteria: * patients who completed hcv-05-002 only * 18-65 years of age, inclusive * primary diagnosis of chronic hcv infection * non-responders to previous pegylated interferon-based therapy exclusion criteria: * patients naive to interferon-based therapy for chronic hcv infection

Keywords: hepatitis c celgosivir hcv genotype 1 non-responders end of treatment response sustained viral response
the efficacy of tbct compared to erp in the treatment of ocd patients, by the assessment of magnetic resonance.

Conditions: OBSESSIVE COMPULSIVE DISORDER (OCD)

Summary: this is a sample made up of ninety-six adult individuals of both sexes to be divided into three groups: the experimental group of thirty-two patients with ocd who will be undergone trial-based cognitive therapy; the gold standard, with thirty-two people with ocd subject exposure and response prevention and the control group of thirty-two healthy individuals. interviews and therapeutic intervention occur in private practices researchers or medical schools accredited by uespi. experimental group: will be eligible adults of both sexes with educational level equal to or higher education complete primary, aged between 18 and 60 years with ocd diagnosis confirmed according to criteria dsm-iv (apa, 1994). it is going to be excluded patients who had previously undergone treatment behavioral psychotherapy or cognitive-behavioral approach.

objectives evaluate the effectiveness of trial-based cognitive therapy (tbct) compared to exposure and response prevention (erp) in the treatment of ocd patients, by neuroimaging tests such as mri. 1. describe the neuroanatomical profile of the sample participants before and after the psychotherapeutic intervention by mri; 2. compare the profile neuroanatomical between the experimental group and the control group by mri; 3. identify possible neuroanatomical differences in the participating sample of pre and post-treatment, both among individuals and among psychotherapeutic intervention groups; 4. to investigate associations between the results of mri scans and indexes the scales currently used to assess severity of ocd.

Eligibility criteria:
inclusion criteria: * will be eligible adults of both sexes with educational level equal to or higher education complete primary, aged between 18 and 60 years with ocd diagnosis confirmed according to criteria dsm-iv exclusion criteria: * it is going to be excluded patients who had previously undergone treatment behavioral psychotherapy or cognitive-behavioral approach.
pet/mr imaging in patients with cardiac amyloidosis

Conditions: Cardiac Amyloidosis

Summary: pet scanning (positron emission tomography) is a well-established technique used to identify areas of interest within the body. it involves injecting a radioactive tracer which highlights abnormal areas. it has recently been combined with ct (computed tomography) and mri (magnetic resonance imaging) scanning to more accurately identify abnormalities within the heart. cardiac amyloidosis, a condition which causes thickening of heart muscle due to abnormal protein deposits, is of particular interest. there are different forms of this condition and at present samples of tissue need to be taken and analysed in order to assess these accurately, which carries risks. the study makes use of hybrid pet/mr scanning using a designated scanner which enables pet scanning combined with mri scanning. the investigators will use a pet tracer which is widely used in cardiac imaging as it is hoped this will enable characterisation of abnormal areas within the heart in this condition in a way which hasn't been done before. all participants will undergo pet scanning, where a radioactive tracer is injected into a vein before the scan. the radioactive substance only lasts for a short time and is safe, passed out of the body in urine. if successful, this imaging method will enable us to detect differences between different forms of cardiac amyloidosis in a non-invasive way, improving the diagnostic capabilities in this condition.


Eligibility criteria:
inclusion criteria: * aged over 40 years * completion of informed consent * established diagnosis of cardiac amyloidosis exclusion criteria: * inability or unwilling to give informed consent * women who are pregnant, breastfeeding or of child-bearing potential (women who have experienced menarche, are pre-menopausal and have not been sterilised) will not be enrolled into the trial. * major intercurrent illness with life-expectancy \<2 years. * renal dysfunction (egfr less than or equal to 30ml/min/1.73m2) * adverse reaction or hypersensitivity to 18f-fdg pet tracer * nyha class iv heart failure * patients with atrial fibrillation and poor rate control * contraindications to mri scanning * previous history of contrast allergy of adverse reactions (gadolinium-containing agents)
circulating mir-126 as a novel biomarker for post myocardial infarction remodeling

Conditions: Myocardial Infarction; Left Ventricular Remodeling; miR-126

Summary: purpose: the purpose of this study is to evaluate the impact of circulating mir-126 on left ventricular remodeling and clinical outcomes in patients undergoing primary percutaneous coronary intervention for st-segment elevation myocardial infarction.


Eligibility criteria:
inclusion criteria: * admitted for primary pci for stemi involving the lad within 12 hours of onset of symptoms. stemi will be defined as typical ecg changes (st segment elevation ≥2mm in 2 or more precordial leads) associated with acute chest pain or an elevation of cardiac enzymes; * age ≥18 years; * informed consent from patient or next of kin. exclusion criteria: * nonischaemic cardiomyopathy; * cardiac surgery planed in the 6 months; * mechanical complication of stemi (ventricular septal rupture, free wall rupture, acute severe mitral regurgitation); * renal or hepatic failure; * malignancy, hiv, or central nervous system disorder; * cardiopulmonary resuscitation \>15 min and compromised level of consciousness; * cardiogenic shock; * current participation in any research study involving investigational drugs or devices; * no written consensus; * previous myocardial infarction.

Keywords: mir-126 left ventricular remodeling myocardial infarction primary percutaneous coronary intervention left ventricular end diastolic volume left ventricular ejection fraction major adverse cardiovascular events
effect of dry needling on surface electromyographic activity in latent trigger points

Conditions: Trigger Point Pain, Myofascial

Summary: brief summary: the purpose of this study is to determine the effect of dry needling (dn) on electromyographic activity in different situations at the latent trigger point (ltrp) point of the upper trapezius. randomized controlled trial, in parallel with the crossover control design. two groups with ltrp in the upper trapezius, and the dn group or the sham-dn group will be randomly selected.


Eligibility criteria:
inclusion criteria: * age between 18 and 30 years * the presence of ltrp in the middle third of the upper trapezius muscle onthe dominant side * being able to provide written informed consent * being able to follow instructions and realize clinical tests exclusion criteria: * any pharmacological therapeutic * any medical treatment or physical therapies at cervical region during the 6-month before this study * any diagnosed health problem * any history of head and upper extremity surgery or trauma * any red flags to dn, (ie: metabolic diseases, pregnancy, kinesiophobia,infection, cancer)• absence of recurrent history of neck pain * no neck pain symptomatology the previous 6 months * cervical disk herniation

Keywords: dry needling electromyography latent trigger point
immune biomarkers of outcome from covid-19

Conditions: COVID-19

Summary: a new virus to humans, first identified in december 2019, is causing a global pandemic with over 1 million infections and many thousands of deaths. the virus, sars-cov2, leads to coronavirus disease 2019 (covid-19), which mainly affects the breathing system. around 1 in every 5 people with covid-19 have more severe infection needing treatment in hospital. up to half of them require help with breathing in an intensive care unit. information we have so far about covid-19 suggests that people with underlying conditions, such as high blood pressure and heart disease, or older people are at higher risk of having severe illness. scientists do not yet understand why but think it may be related to the immune system. sars-cov2 activates the immune system causing inflammation in the lungs, which is also seen in circulating immune cells in the blood. preliminary reports show that the response of the immune system can be inappropriate, both overactive and also poorly responsive (exhausted). changes in the type and function of immune cells have been linked to increased risk of severe disease or death from covid-19. in this study, the investigators will look for markers of immune function when a person first attends hospital, which can be used to predict whether they will go on to have a more severe infection. this will help treat patients more effectively, for example, by moving high risk patients to an intensive care setting at an early stage. the team will investigate the immune system in detail in 200 patients with covid-19 attending university hospitals plymouth. the investigators will look for changes in the number, type and function of circulating immune cells and measure whether these changes are linked to severity of the infection or death. the investigators will use established techniques to measure immune function that could be rapidly put into routine hospital care to help guide treatment for individual patients.


Eligibility criteria:
inclusion criteria: * patients attending uhp with covid-19 infection * participants capable of giving informed consent, or if not capable, assent from a personal or nominated consultee * age of 18 or over * confirmed covid-19 infection by pcr or antibody testing exclusion criteria: * participants on immune suppressing medications within preceding 4 weeks (including systemic corticosteroids with average daily dose equivalent to prednisolone 20 mg) * participants on treatment with systemic chemotherapy * participants with known immunodeficiency states * participants already administered immunomodulating or antiviral agents as part of an interventional trial (this does not include non-specific therapies such as hydroxycholoroquine)

Keywords: inflammation immune response biomarker
a pilot study to evaluate the use of c1 esterase inhibitor (human) in patients with acute antibody-mediated rejection

Conditions: Graft Rejection

Summary: the purpose of this research study is to evaluate the safety, effect, and pharmacology of c1 esterase inhibitor (human) in kidney transplant patients with acute antibody-mediated rejection (amr).


Eligibility criteria:
inclusion criteria include: * ≥18 years of age. * weigh ≥50 kg. * donor specific antibody identified. exclusion criteria include: * any surgical or medical condition that could interfere with the administration of study drug or interpretation of study results. * history of allergic reaction to c1 esterase inhibitor or other blood products. * participation in the active dosing phase of any other investigational drug study within 30 days prior to dosing with study drug. * pregnancy or lactation. * receipt of any experimental agents for amr within 1 month prior to the first dose of study drug. * any infection that causes hemodynamic compromise. * history of bleeding or clotting abnormality.
pain management in laparoscopic cholecystectomies

Conditions: Nerve Block

Summary: erector spinae plane (esp) block is a more recent method than paravertebral block (pvb) and has a lower risk of complications. the aim of this study was to compare postoperative analgesia requirements and side-effects in terms of safely reaching the maximum analgesic effect in patients.

the primary aim of this study was to compare esp block and pvb as important postoperative pain management in terms of being able to reliably reach the highest analgesic efficacy in patients who underwent laparoscopic surgery which is a frequently applied surgery. the secondary aim was to determine the incidence of postoperative nausea, vomiting and side-effects, and patient satisfaction.

Eligibility criteria:
inclusion criteria: * aged \>18 years * patients with the american society of anesthesiologists (asa) physical status i/ii -who were planned to undergo laparoscopic cholecystectomy surgery exclusion criteria: * did not provide informed consent, * had any psychiatric or mental problem that prevented understanding of the informed consent form * they were planned to undergo emergency cholecystectomy, * had any allergy or hypersensitivity to local anaesthetic, * had an infection in the needle entry area * history of coagulopathy or the use of anticoagulants

Keywords: erector spinae plane block paravertebral block laparoscopic cholecystectomy